NewswireToday - /newswire/ -
San Jose, CA, United States, 2015/11/12 - BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it has received Frost & Sullivan’s 2015 Global Company of the Year Award for Clinical and Research Flow Cytometry - Frost.com / BD.com. NYSE: BDX
Frost & Sullivan analysts independently evaluate candidates for the Global Company of the Year Award based on three key factors: visionary innovation, performance and customer impact. BD was recognized for its large and diverse customer base, broad product portfolio, consistent track record of reliability and supply chain excellence, and quality customer service among other factors.
“BD offers robust products that incorporate innovative hardware, software, multiple reagents (including a broad portfolio of bright fluorescent dyes), an automated setup and stringent quality control,” said Divyaa Ravishankar, team leader - senior industry analyst and associate fellow at Frost & Sullivan. “In addition to being first to market, BD has established clear credibility for its products among end users.”
BD’s principal Biosciences product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media and supplements for biopharmaceutical manufacturing.
“We are honored to be recognized by Frost & Sullivan,” said Claude Dartiguelongue, worldwide president of Biosciences for BD. “For more than 40 years, BD has partnered with our global research and clinical customers to expand knowledge of the single cell. Today, these discoveries and applications help to improve the diagnosis and understanding of many different diseases impacting the world.”
BD (bd.com) is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions.